Chagas disease is most often transmitted to humans by Trypanosoma cruzi infected triatomine bugs， and remains a significant cause of morbidity and mortality in Central and South America. Control of Chagas disease has relied mainly on vector eradication. However， development of insect resistance has prompted us to develop a paratransgenic strategy to control vectorial transmission of T. cruzi. Here， the potential role of recombinant endoglucanases as anti-trypanosomal agents for paratransgenic application is examined. The surface of T. cruzi is covered by a thick coat of mucin-like glycoproteins that have been proposed to play a role in the binding of T. cruzi to the membrane surface of the vector gut. We hypothesize that disruption of these glycoconjugates could arrest parasite development in the vector and abort the transmission cycle. In this work， we examine the effects of recombinant Arthrobacter luteus β-1， 3-glucanase expressed via Rhodococcus rhodnii on T. cruzi Sylvio II strain.